Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer

Table 1 Baseline patients’ characteristics, n (%)

Variable	GA (n = 54)	FOLFIRINOX (n = 47)	P value
Age (yr)	65.7 ± 7.8	64.4 ± 8.4	0.445
Male	39 (72.2)	31 (66.0)	0.501
Body weight (kg)	59.2 ± 9.5	58.5 ± 9.9	0.716
Height (m)	1.65 ± 0.08	1.63 ± 0.07	0.352
Body mass index (kg/m2)	21.9 ± 3.1	22.0 ± 3.5	0.852
Psoas muscle area (cm2)	8.6 ± 2.9	8.3 ± 2.1	0.639
Number of metastasis ≥ 2	48 (88.9)	35 (74.5)	0.060
Liver meta	32 (59.3)	31 (66.0)	0.493
Carcinomatosis peritonei	21 (38.9)	16 (34.0)	0.618
Lung meta	13 (24.1)	8 (17.0)	0.389
Primary tumor site			0.778
Head	25 (46.3)	25 (53.2)
Body	14 (25.9)	8 (17.0)
Tail	15 (27.8)	14 (29.8)
ECOG performance status			0.018a
0 or 1	48 (88.9)	47 (100)
2	6 (11.1)	0 (0)
Diabetes	22 (40.7)	23 (48.9)	0.414
Hypertension	12 (22.2)	12 (25.5)	0.700
Laboratory findings
White blood cell (/µL)	6465.6 ± 2743.0	9780.0 ± 16931.6	0.159
Platelet (103/µL)	235.9 ± 122.4	270.1 ±107.7	0.142
Neutrophil/lymphocyte ratio	3.72 ± 2.98	3.0 ± 1.87	0.167
Pletelet/lymphocyte ratio	190.2 ± 120.7	159.5 ± 71.0	0.129
C-related protein (mg/dL)	1.49 ± 2.23	1.29 ± 2.00	0.641
Albumin (g/dL)	3.92 ± 0.46	3.98 ± 0.57	0.552
Total bilirubin (mg/dL)	1.41 ± 3.06	1.42 ± 1.60	0.988
CA 19-9 (U/mL)	12881.3 ± 54407.2	1307.1 ± 2079.1	0.153

^aP < 0.05, mean ± SD. GA: Gemcitabine plus nab-paclitaxel; ECOG: Eastern Cooperative Oncology Group; CA: Carbohydrate antigen.